Biobohemia's strategy is based on development and rapid clinical entry of SANTAVAC cancer vaccines based on antiangiogenic essences, demonstration of clinical safety and efficacy of this approach, and follow-on development of additional immunotherapeutic candidates. This strategy will allow for the leveraging of initial development efforts of the most advanced candidate to allow expedient transition for the other candidates. Biobohemia's therapeutic pipeline includes technologically distinct candidate products:
- Therapeutic SANTAVAC15 DC is an antiangiogenic SANTAVAC15-loaded allogeneic dendritic cell vaccine for autologous cell therapy, for production of which primary culture of allogeneic HMECs can be purchased to produce SANTAVAC; DCs should be obtained from patient's blood.
- Preventive SANTAVAC25 DC is an antiangiogenic SANTAVAC25-loaded allogeneic dendritic cell vaccine for autologous cell therapy, for production of which commercially available allogeneic HMECs can be purchased to produce SANTAVAC; DCs should be obtained from patient's blood.
- Therapeutic SANTAVAC15 vaccine is a peptide vaccine composed of allogeneic SANTAVAC15 mixed with adjuvant.
- Preventive SANTAVAC25 vaccine is a peptide vaccine composed of allogeneic SANTAVAC25 mixed with adjuvant.
In addition to encompassing technologically distinct candidates, the therapeutic pipeline encompasses separate formulations that can also target different types of cancer. Notwithstanding, the development programs are all highly focused on one target: antigen compositions developed by antigenic essence technology and intended for the development of cancer vaccines against solid tumors. This circumstance simplifies the overall R&D efforts and creates synergy among all of the programs, allowing the programs and their associated achievements to leverage each other. The development programs may be corrected according to the results of animal testing.